Letters to the Editor

Direct and indirect anti-leukemic properties of Activity-on-Target interferons for the treatment of T-cell acute lymphoblastic leukemia

Cancer Research Institute Ghent (CRIG), Ghent University, B-9000 Ghent, Belgium; Department of Diagnostic Sciences, Ghent University, B-9000 Ghent, Belgium; Department of Biomolecular Medicine, Ghent University, B-9000 Ghent
Cancer Research Institute Ghent (CRIG), Ghent University, B-9000 Ghent, Belgium; Department of Biomolecular Medicine, Ghent University, B-9000 Ghent, Belgium; VIB-UGent Center for Medical Biotechnology, B-9000 Ghent, Belgium; Orionis Biosciences BV, B-9052 Ghent
Cancer Research Institute Ghent (CRIG), Ghent University, B-9000 Ghent, Belgium; Department of Biomolecular Medicine, Ghent University, B-9000 Ghent
Cancer Research Institute Ghent (CRIG), Ghent University, B-9000 Ghent, Belgium; Department of Biomolecular Medicine, Ghent University, B-9000 Ghent
Cancer Research Institute Ghent (CRIG), Ghent University, B-9000 Ghent, Belgium; Department of Biomolecular Medicine, Ghent University, B-9000 Ghent
Cancer Research Institute Ghent (CRIG), Ghent University, B-9000 Ghent, Belgium; Department of Biomolecular Medicine, Ghent University, B-9000 Ghent
Cancer Research Institute Ghent (CRIG), Ghent University, B-9000 Ghent, Belgium; Department of Hematology, Ghent University Hospital, B-9000 Ghent
Cancer Research Institute Ghent (CRIG), Ghent University, B-9000 Ghent, Belgium; Department of Biomolecular Medicine, Ghent University, B-9000 Ghent
Cancer Research Institute Ghent (CRIG), Ghent University, B-9000 Ghent, Belgium; Department of Biomolecular Medicine, Ghent University, B-9000 Ghent, Belgium; VIB-UGent Center for Medical Biotechnology, B-9000 Ghent, Belgium; Orionis Biosciences BV, B-9052 Ghent
Haematologica Early view Oct 14, 2021 https://doi.org/10.3324/haematol.2021.278913